Theophylline, a nonspecific phosphodiesterase (PDE) inhibitor and bronchodilator, was identified to improve HDAC2 expression in COPD, which led to examining its potential to improve corticosteroid sensitivity in patients with COPD. The gene discussed is HDAC2; the disease is chronic obstructive pulmonary disease.